AVA Submission to the TGA Lidocaine rescheduling

11 Sep 2022

The TGA has made the interim decision to not amend the existing Schedule 5 entry for lidocaine "in injectable preparations containing 2 per cent or less of lidocaine when packaged in a container with a tamper resistant cartridge which can only be dispensed through a rubber ring applicator for tail docking and castration of lambs, or castration of calves"

It is the AVA’s view that the Committee and Delegate have based their decision on a number of misconceptions:

  1. The conclusion that “significant animal welfare benefits” outweigh the risks.
  2. Risks of misuse or harm in target and non-target species
  3. Basis of assessment of public opinion
  4. Assertion that rescheduling the product will lead to improved human mental health
  5. Assertion that there are barriers to access
  6. Assertion that the potential for diversion and inappropriate use is low.

Read the full submission here.